Type 1 Diabetes: New and Emerging Therapeutic Strategies to Address Unmet Needs / Advancements in the Clinical Approach and Therapy in Type 1 Diabetes

A CME Enduring Program

CME Webcast

Click to participate!

Presenter Slide Decks

Download the presentation slide decks!

Term of Offering:  This activity was released on July 12, 2019 and is valid for one year. Requests for credit must be made no later than July 12, 2020.

Fee Information & Refund/Cancellation Policy:  This educational activity is complimentary.

CME WITH TCOYD

COURSE DESCRIPTION

This program aims to educate healthcare professionals about the unmet needs of individuals living with type 1 diabetes. The presentation will focus on the new adjunctive therapeutic options and strategies to improve clinical care of this very difficult condition in order to achieve adequate glycemic control and improve other important related conditions. In addition to insulin strategies for type 1 diabetes and the use of continuous glucose monitoring, the recent clinical data from the use of sodium glucose transporter (SGLT) inhibitors in type 1 diabetes will be discussed in detail.

WHAT YOU CAN EXPECT TO LEARN

After completing this activity, the participant should be better able to:

• Summarize approaches to initiating, switching and adjusting basal and prandial insulins for improved glycemic control.
• Discuss physician and patient-directed insulin titration strategies used in clinical practice, which are different from those used in type 2 diabetes.
• Outline the most up to date clinical information on therapies other than insulin, including SGLT-2 and SGLT-1/2 inhibitors, for people with type 1 diabetes other than insulin.
• Describe practical considerations for initiating therapies other than insulin in type 1 diabetes.
• Discuss the information that continuous glucose monitoring technology provides.
• Describe effective therapeutic adjustments based on the trending or rate of change (ROC) arrows provided by CGM data.

SPEAKERS & FACULTY

*extra-relatable faculty (they’re living with type 1)

*Steven V. Edelman, MD
TCOYD Founder & Director

Dr. Edelman is the founder and director of Taking Control Of Your Diabetes (TCOYD), a professor of medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California, San Diego (UCSD) and the Veterans Affairs (VA) Healthcare System of San Diego. He is also the director of the Diabetes Care Clinic at the VA Medical Center. Dr. Edelman, who has type 1 diabetes himself, has written more than 200 articles, five books, and has won numerous awards for teaching and humanitarianism. He has been chosen by the medical students at UCSD as the ‘teacher of the year’ numerous times. Among his many honors, Dr. Edelman has received the ‘Diabetes Educator Of The Year’ award by the American Diabetes Association, the ‘Distinction in Endocrinology’ award by the American Association of Clinical Endocrinologists, and named ‘Top 1% of U.S. Endocrinologists’ by US News and World Report.

*Jeremy Pettus, MD
Type 1 Track Co-Director, Endocrinologist, Assistant Professor of Medicine, UCSD School of Medicine

Dr Jeremy Pettus was diagnosed with type 1 diabetes when he was 15 years old.  Since that time he has dedicated his career to educating and treating others like himself.  He is currently an Endocrinologist and Assistant Professor of Medicine at the University of California, San Diego.  There, he focuses primarily on clinical trials to develop and test new and innovative therapies for people living with diabetes.  These include studies ranging from medications to reverse or slow the disease once it occurs, to islet cell transplantation strategies, to device studies such as artificial pancreas technology.  As somebody who has the disease himself, sees patients with type 1, and is actively working on curing/treating the disease, we are honored to have him as our Type 1 Track director.  Dr. Pettus travels across the country and the world meeting other leading physicians and scientists and brings this information directly to TCOYD conference participants.

TARGET AUDIENCE

This course is designed for diabetes healthcare providers including endocrinologists, primary care physicians, nurse practitioners, physician assistants, nurses, certified diabetes educators, pharmacists, and other healthcare providers wanting to expand their knowledge of diabetes management.

ACCREDITATION INFORMATION

Accreditation

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Taking Control of Your Diabetes.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

Credit Designation
Global Education Group designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – 0530-9999-19-089-H01-P – this number is different than what is on the current accreditation webpage for type 1 new and emerging insulins
This is a knowledge based activity.

 Instructions to Receive Credit  *(ACPE Only)
Participants must also score at least a 70% on the post-test and submit it.

Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Pharmacist Accreditation Statement

DISCLOSURES

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Steven V. Edelman: Board Member: Senseonics; Medical Advisory Board: AstraZeneca, Companion Medical, Lexicon, Lilly USA, LLC, Mannkind Corporation, Merck, Sanofi-aventis U.S. Inc.; Speaker’s Bureau: AstraZeneca, Lilly USA LLC, Mannkind Corporation, Merck, Sanofi-aventis U.S. Inc.

Jeremy H. Pettus: Consultant: Diasome, Eversense, Insulet, Lilly USA, LLC, Mannkind Corporation, Novo Nordisk, Sanofi-aventis U.S. Inc.; Research Funding: Novo Nordisk

 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, BSN: Nothing to disclose

Lindsay Borvansky: Nothing to disclose

Karen Kaufman: Nothing to disclose

Andrea Funk: Nothing to disclose

Liddy Knight: Nothing to disclose

Robyn Perez:  Nothing to disclose

 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Taking Control Of Your Diabetes (TCOYD) do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Sanofi US and Lexicon Pharmaceuticals, Inc.

This activity is jointly provided by Global Education Group and Taking Control Of Your Diabetes.

Logos